Identification

Name
Promethazine
Accession Number
DB01069  (APRD00601)
Type
Small Molecule
Groups
Approved
Description

A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. [PubChem]

Structure
Thumb
Synonyms
  • (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine
  • 10-(2-Dimethylaminopropyl)phenothiazine
  • 10-[2-(dimethylamino)Propyl]phenothiazine
  • N-(2'-dimethylamino-2'-Methyl)ethylphenothiazine
  • N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine
  • N,N,α-trimethyl-10H-phenothiazine-10-ethanamine
  • Proazamine
  • Prometazina
  • Promethazine
  • Promethazinum
External IDs
Lilly 1516
Product Ingredients
IngredientUNIICASInChI Key
Promethazine hydrochlorideR61ZEH7I1I58-33-3XXPDBLUZJRXNNZ-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Phenergan Injectable 25mg/mlSolution25 mgIntramuscular; IntravenousAventis Pharma Ltd.1949-12-312005-08-01Canada
Promethazine HCl Inj 28.2mg/mlLiquid28.2 mgIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1985-12-311996-09-10Canada
Promethazine HCl Inj USPSolution25 mgIntramuscular; IntravenousAlveda Pharmaceuticals IncNot applicableNot applicableCanada
Promethazine Hydrochloride Injection USPLiquid25 mgIntramuscular; IntravenousSandoz Canada Incorporated1982-12-31Not applicableCanada
Promethazine Hydrochloride Injection, USPSolution25 mgIntramuscular; IntravenousMylan Pharmaceuticals1994-12-312015-11-03Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PhenadozSuppository25 mg/1RectalRemedy Repack2013-05-142017-02-16Us
PhenadozSuppository25 mg/1RectalPaddock Laboratories, Inc.2003-06-24Not applicableUs
PhenadozSuppository25 mg/1RectalWatson Pharmaceuticals2013-04-03Not applicableUs
PhenadozSuppository12.5 mg/1RectalPaddock Laboratories, Inc.2003-06-24Not applicableUs
PhenadozSuppository12.5 mg/1RectalActavis Pharma Company2015-03-16Not applicableUs
PhenadozSuppository12.5 mg/1RectalWatson Pharmaceuticals2013-02-12Not applicableUs
PhenadozSuppository12.5 mg/1RectalPd Rx Pharmaceuticals, Inc.2003-06-24Not applicableUs
PhenadozSuppository25 mg/1RectalActavis Pharma Company2015-02-17Not applicableUs
PhenerganInjection25 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical1973-09-19Not applicableUs
PhenerganInjection50 mg/mLIntramuscularWest Ward Pharmaceutical1973-09-19Not applicableUs
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Histantil Tab 25mgTablet25 mgOralPharmascience Inc1983-12-31Not applicableCanada
Histantil Tab 50mgTablet50 mgOralPharmascience Inc1983-12-31Not applicableCanada
Phenergan 50Tablet50 mgOralColumbia Laboratories1996-12-312002-07-17Canada
Phenergan Cream 2%Cream2 %TopicalRhone Poulenc Rorer1993-12-311997-08-13Canada
Phenergan Cream 2%Cream2 %TopicalColumbia Laboratories1996-07-302007-07-24Canada
Phenergan Syrup 10mg/5mlSyrup10 mgOralRhone Poulenc Rorer1993-12-311996-09-09Canada
Phenergan Tablet 10mgTablet10 mgOralRhone Poulenc Rorer1993-12-311997-08-13Canada
Phenergan Tablet 25mgTablet25 mgOralRhone Poulenc Rorer1993-12-311997-08-13Canada
Phenergan Tablet 25mgTablet25 mgOralNovartis1996-12-311999-07-21Canada
Phenergan Tablet 50mgTablet50 mgOralRhone Poulenc Rorer1992-12-311997-08-13Canada
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Promethazine HClInjection, solution.5 mg/mLIntravenousCantrell Drug Company2014-05-29Not applicableUs
Promethazine HClInjection, solution1 mg/mLIntravenousCantrell Drug Company2014-05-27Not applicableUs
Promethazine HClInjection, solution.625 mg/mLIntravenousCantrell Drug Company2014-05-27Not applicableUs
Promethazine HydrochlorideTablet50 mg/1OralDirectrx2017-10-30Not applicableUs
Promethazine HydrochlorideSolution6.25 mg/5mLOralNu Care Pharmaceuticals,inc.2006-04-26Not applicableUs
International/Other Brands
Avomine / Fargan / Farganesse / Lergigan / Prothiazine / Receptozine / Romergan
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Dextromethorphan Hydrobromide and Promethazine HydrochloridePromethazine hydrochloride (6.25 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL)SyrupOralRemedy Repack2013-12-022016-12-24Us
Dextromethorphan Hydrobromide and Promethazine HydrochloridePromethazine hydrochloride (6.25 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL)SyrupOralProficient Rx LP1985-01-04Not applicableUs
Dextromethorphan Hydrobromide and Promethazine HydrochloridePromethazine hydrochloride (6.25 mg/5mL) + Dextromethorphan hydrobromide (15 mg/5mL)SyrupOralAtlantic Biologicals Corps.1985-01-04Not applicableUs
Meperidine Hydrochloride and Promethazine HydrochloridePromethazine hydrochloride (25 mg/1) + Meperidine hydrochloride (50 mg/1)CapsuleOralEci Pharmaceuticals Llc2013-02-192017-08-29Us
Promatussin DM Adult Formula SyrPromethazine hydrochloride (6.25 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (60 mg)SyrupOralWyeth Ayerst Canada Inc.1993-12-311996-09-10Canada
Promatussin DM Children FormulaPromethazine hydrochloride (3.125 mg) + Dextromethorphan hydrobromide (7.5 mg) + Pseudoephedrine hydrochloride (30 mg)LiquidOralWyeth Ltd.1981-12-311996-09-10Canada
Prometh with CodeinePromethazine hydrochloride (6.25 mg/5mL) + Codeine phosphate (10 mg/5mL)SyrupOralActavis Mid Atlantic LLC,2003-01-032017-06-20Us
Prometh with CodeinePromethazine hydrochloride (6.25 mg/5mL) + Codeine phosphate (10 mg/5mL)SyrupOralRebel Distributors1984-10-31Not applicableUs
Prometh with CodeinePromethazine hydrochloride (6.25 mg/5mL) + Codeine phosphate (10 mg/5mL)SyrupOralRemedy Repack2013-07-082016-10-13Us
Prometh with CodeinePromethazine hydrochloride (6.25 mg/5mL) + Codeine phosphate (10 mg/5mL)SyrupOralbryant ranch prepack2003-01-03Not applicableUs
Categories
UNII
FF28EJQ494
CAS number
60-87-7
Weight
Average: 284.419
Monoisotopic: 284.13471934
Chemical Formula
C17H20N2S
InChI Key
PWWVAXIEGOYWEE-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
IUPAC Name
dimethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine
SMILES
CC(CN1C2=CC=CC=C2SC2=CC=CC=C12)N(C)C

Pharmacology

Indication

For the treatment of allergic disorders, and nausea/vomiting.

Structured Indications
Pharmacodynamics

Promethazine, a phenothiazine, is an H1-antagonist with anticholinergic, sedative, and antiemetic effects and some local anesthetic properties. Promethazine is used as an antiemetic or to prevent motion sickness.

Mechanism of action

Like other H1-antagonists, promethazine competes with free histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. The relief of nausea appears to be related to central anticholinergic actions and may implicate activity on the medullary chemoreceptor trigger zone.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UD(2) dopamine receptor
antagonist
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M4
antagonist
Human
UMuscarinic acetylcholine receptor M5
antagonist
Human
UAlpha-1A adrenergic receptor
unknown
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
UCalmodulin
inhibitor
Human
UHistamine H2 receptor
antagonist
Human
Absorption

On average, 88% of a promethazine dose is absorbed after oral administration; however, the absolute bioavailability is only 25% because of first-pass clearance.

Volume of distribution
Not Available
Protein binding

93%

Metabolism

Hepatic

Route of elimination

Promethazine hydrochloride is metabolized in the liver, with the sulfoxides of promethazine and N-desmethylpromethazine being the predominant metabolites appearing in the urine.

Half life

16-19 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include mild depression of the central nervous system and cardiovascular system to profound hypotension, respiratory depression, unconsciousness, and sudden death. Other reported reactions include hyperreflexia, hypertonia, ataxia, athetosis, and extensor-plantar reflexes (Babinski reflex). LD50=55mg/kg (I.V. in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Promethazine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Promethazine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Promethazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Promethazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Promethazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Promethazine.Experimental
AbirateroneThe serum concentration of Promethazine can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Promethazine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Promethazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Promethazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Promethazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Promethazine.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Promethazine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Promethazine.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Promethazine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Promethazine is combined with Alaproclate.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Promethazine.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Promethazine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Promethazine.Approved, Illicit
AlgeldrateAlgeldrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Promethazine.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Promethazine.Investigational
AlmagateAlmagate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmasilateAlmasilate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Promethazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Promethazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Promethazine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promethazine.Approved, Illicit, Investigational
AlprenololPromethazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Promethazine.Approved, Investigational
AmiodaronePromethazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Promethazine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promethazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Promethazine.Approved, Illicit
AmodiaquineThe serum concentration of Promethazine can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Promethazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Promethazine.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Promethazine.Approved, Illicit
AnagrelidePromethazine may increase the QTc-prolonging activities of Anagrelide.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Promethazine.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Promethazine is combined with Aripiprazole.Approved, Investigational
ArotinololPromethazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxidePromethazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPromethazine may increase the QTc-prolonging activities of Artemether.Approved
ArtemisininThe serum concentration of Promethazine can be increased when it is combined with Artemisinin.Investigational
ArtemotilThe serum concentration of Promethazine can be increased when it is combined with Artemotil.Experimental
ArtenimolThe serum concentration of Promethazine can be increased when it is combined with Artenimol.Approved
ArtesunateThe serum concentration of Promethazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Promethazine.Approved
AsenapinePromethazine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Promethazine.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Promethazine.Approved
AtomoxetineThe metabolism of Promethazine can be decreased when combined with Atomoxetine.Approved
AtovaquoneThe serum concentration of Promethazine can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Promethazine.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Promethazine.Vet Approved
AzelastinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinPromethazine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Promethazine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Promethazine.Illicit
BedaquilinePromethazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololPromethazine may increase the hypotensive activities of Befunolol.Experimental
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Promethazine.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Promethazine.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Promethazine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Promethazine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Promethazine.Approved
Benzylpenicilloyl PolylysinePromethazine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Promethazine.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Promethazine.Approved, Vet Approved
BetaxololThe metabolism of Promethazine can be decreased when combined with Betaxolol.Approved
BevantololPromethazine may increase the hypotensive activities of Bevantolol.Approved
BezitramidePromethazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Promethazine is combined with Bifeprunox.Investigational
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BisoprololPromethazine may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Promethazine.Withdrawn
BopindololPromethazine may increase the hypotensive activities of Bopindolol.Approved
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Promethazine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Promethazine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Promethazine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Promethazine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Promethazine.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Promethazine is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Promethazine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promethazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Promethazine.Approved, Withdrawn
BucindololPromethazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolPromethazine may increase the hypotensive activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promethazine.Approved, Investigational
BupranololPromethazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Promethazine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Promethazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promethazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Promethazine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Promethazine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Promethazine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Promethazine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promethazine.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Promethazine.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promethazine.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Promethazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Promethazine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Promethazine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Promethazine.Investigational
CarbamazepineThe metabolism of Promethazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Promethazine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Promethazine.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Promethazine.Approved
CariprazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Promethazine.Approved
CarteololPromethazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolPromethazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Promethazine.Approved
CefpodoximePromethazine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximePromethazine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CelecoxibThe metabolism of Promethazine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololPromethazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibPromethazine may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Promethazine.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Promethazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Promethazine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Promethazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Promethazine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Promethazine.Approved
ChloroquineThe serum concentration of Promethazine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Promethazine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Chlorproethazine.Experimental
ChlorproguanilThe serum concentration of Promethazine can be increased when it is combined with Chlorproguanil.Investigational
ChlorpromazinePromethazine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Promethazine.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promethazine.Approved
CholecalciferolThe metabolism of Promethazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Promethazine.Approved
CinacalcetThe metabolism of Promethazine can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Promethazine.Approved, Vet Approved
CiprofloxacinPromethazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisapridePromethazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Promethazine.Approved
CitalopramPromethazine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinPromethazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Promethazine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Promethazine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Promethazine.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Promethazine.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Promethazine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Promethazine.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Promethazine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Promethazine.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Promethazine.Approved, Nutraceutical
CloranololPromethazine may increase the hypotensive activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Promethazine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Promethazine.Experimental
ClotrimazoleThe metabolism of Promethazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapinePromethazine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Promethazine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Promethazine.Approved
CocaineThe metabolism of Promethazine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Promethazine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Promethazine.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Promethazine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Promethazine.Approved
CrizotinibPromethazine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.Approved
Cycloguanil embonateThe serum concentration of Promethazine can be increased when it is combined with Cycloguanil embonate.Experimental
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Promethazine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Promethazine.Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Promethazine.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Promethazine.Approved
DabrafenibThe serum concentration of Promethazine can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Promethazine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Promethazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promethazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Promethazine.Investigational
DapsoneThe serum concentration of Promethazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Promethazine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Promethazine can be increased when it is combined with Darunavir.Approved
DasatinibPromethazine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Promethazine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Promethazine.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Promethazine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Promethazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Promethazine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Promethazine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Promethazine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Promethazine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Promethazine.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Promethazine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Promethazine.Approved, Vet Approved
DexmethylphenidatePromethazine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Promethazine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Promethazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Promethazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promethazine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Promethazine.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Promethazine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Promethazine.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Promethazine.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Promethazine.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Promethazine is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Promethazine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Promethazine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promethazine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promethazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promethazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promethazine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Promethazine.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Promethazine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Promethazine.Approved
DiphenhydramineThe metabolism of Promethazine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promethazine.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Promethazine.Approved
DisopyramidePromethazine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Promethazine.Experimental
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Promethazine.Approved, Investigational
DofetilidePromethazine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronPromethazine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePromethazine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Promethazine.Vet Approved
DosulepinThe metabolism of Promethazine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Promethazine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Promethazine.Approved, Investigational
DoxycyclineThe serum concentration of Promethazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Promethazine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Illicit
DronedaronePromethazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Promethazine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Promethazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Promethazine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Promethazine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Promethazine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Promethazine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Promethazine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Promethazine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promethazine.Approved, Investigational
EliglustatPromethazine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Promethazine.Investigational
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Promethazine.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Promethazine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Promethazine.Approved, Investigational
EpanololPromethazine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Promethazine.Approved, Investigational
EpinephrinePromethazine may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promethazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promethazine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Promethazine.Approved, Investigational
ErythromycinPromethazine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramPromethazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EsmololPromethazine may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Promethazine.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Promethazine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Promethazine.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Promethazine.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promethazine.Approved
EthanolPromethazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promethazine.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Promethazine.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Promethazine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Promethazine.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Promethazine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Promethazine.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Promethazine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promethazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Promethazine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Promethazine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Promethazine.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Promethazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Promethazine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Promethazine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Promethazine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Promethazine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Promethazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Promethazine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promethazine.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltosePromethazine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitratePromethazine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphatePromethazine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Promethazine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Promethazine.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Promethazine.Approved
FlecainidePromethazine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Promethazine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Promethazine.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Promethazine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Promethazine.Approved, Illicit
FluoxetinePromethazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPromethazine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Promethazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Promethazine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Promethazine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Promethazine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Promethazine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Promethazine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Promethazine.Approved
FosphenytoinThe metabolism of Promethazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Promethazine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Promethazine.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Promethazine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Promethazine is combined with Gabapentin Enacarbil.Approved
Gadobenic acidPromethazine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Promethazine.Approved, Illicit, Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Promethazine.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Promethazine.Approved
GemifloxacinPromethazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Promethazine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Promethazine.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Promethazine.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Promethazine.Approved, Illicit
GoserelinPromethazine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronPromethazine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Promethazine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Promethazine.Investigational, Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Promethazine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Promethazine.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Promethazine can be increased when it is combined with Halofantrine.Approved
HaloperidolPromethazine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Promethazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Promethazine.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Promethazine.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Promethazine.Approved, Investigational
HydrocodonePromethazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Promethazine.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promethazine.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Promethazine.Approved
HydroxychloroquineThe serum concentration of Promethazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Promethazine.Approved
IbutilidePromethazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Promethazine.Approved
IloperidonePromethazine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Promethazine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Promethazine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Promethazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Promethazine is combined with Indalpine.Investigational, Withdrawn
IndenololPromethazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Promethazine.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Promethazine.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Promethazine.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Promethazine.Approved
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Promethazine.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Promethazine.Approved, Investigational
IronPromethazine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranPromethazine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharatePromethazine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Promethazine is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Promethazine.Approved, Vet Approved
IsoniazidThe metabolism of Promethazine can be decreased when combined with Isoniazid.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Promethazine.Approved, Investigational
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Promethazine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Promethazine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Promethazine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promethazine.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Promethazine.Approved, Investigational
LabetalolPromethazine may increase the hypotensive activities of Labetalol.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Promethazine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Promethazine.Approved, Investigational
LandiololPromethazine may increase the hypotensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Promethazine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Promethazine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Promethazine.Approved
LenvatinibPromethazine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolidePromethazine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Promethazine.Approved, Investigational
LevobunololPromethazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Promethazine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Promethazine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Promethazine is combined with Levodopa.Approved
LevofloxacinPromethazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promethazine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Promethazine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promethazine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Promethazine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Promethazine.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Promethazine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Promethazine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Promethazine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Promethazine.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Promethazine.Approved
LopinavirPromethazine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Promethazine.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Promethazine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promethazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Promethazine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Promethazine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Promethazine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promethazine.Approved
LumacaftorThe serum concentration of Promethazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePromethazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Promethazine can be decreased when combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Promethazine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promethazine.Approved
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Promethazine.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Promethazine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Promethazine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Promethazine.Vet Approved
MefloquineThe serum concentration of Promethazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Promethazine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Promethazine.Approved
MephedroneMephedrone may decrease the sedative activities of Promethazine.Investigational
MephentermineMephentermine may decrease the sedative activities of Promethazine.Approved
MepindololPromethazine may increase the hypotensive activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Promethazine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Promethazine.Experimental
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Promethazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Promethazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Promethazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Promethazine.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Promethazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Promethazine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Promethazine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Promethazine.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Promethazine.Approved
MethotrimeprazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promethazine.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Promethazine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Promethazine.Experimental
MethylphenidatePromethazine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Promethazine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Promethazine.Approved, Vet Approved
MetipranololPromethazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Promethazine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Promethazine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Promethazine.Approved, Illicit
Midomafetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Promethazine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Promethazine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Promethazine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Promethazine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Promethazine.Approved
MirtazapinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Promethazine.Approved, Investigational
MizoribineThe serum concentration of Promethazine can be increased when it is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Promethazine.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Promethazine is combined with Moclobemide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Promethazine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Moperone.Experimental
MorphineThe serum concentration of Morphine can be increased when it is combined with Promethazine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Promethazine is combined with Mosapramine.Experimental
MoxifloxacinPromethazine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Promethazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Promethazine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promethazine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Promethazine.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Promethazine.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promethazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Promethazine.Approved
NevirapineThe metabolism of Promethazine can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Promethazine.Approved
NicomorphinePromethazine may increase the hypotensive activities of Nicomorphine.Experimental
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Promethazine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Promethazine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Promethazine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Promethazine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Promethazine.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Promethazine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Promethazine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Promethazine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promethazine.Approved
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Promethazine.Investigational
OfloxacinPromethazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Promethazine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Promethazine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Promethazine.Approved
OndansetronPromethazine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Promethazine.Approved, Illicit
OrphenadrinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Promethazine.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Promethazine.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Promethazine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Promethazine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promethazine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Promethazine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Promethazine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promethazine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Promethazine is combined with Oxypertine.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Promethazine.Approved, Vet Approved
PaliperidonePromethazine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Promethazine.Approved, Investigational
PanobinostatThe serum concentration of Promethazine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydePromethazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe metabolism of Promethazine can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Promethazine.Approved
Peginterferon alfa-2bThe serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPromethazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Promethazine.Experimental
PentamidinePromethazine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promethazine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promethazine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Promethazine.Investigational
PerflutrenPromethazine may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Promethazine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Promethazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promethazine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Promethazine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promethazine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Promethazine.Experimental
PhenobarbitalThe metabolism of Promethazine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Promethazine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Promethazine.Approved
PhenterminePhentermine may decrease the sedative activities of Promethazine.Approved, Illicit
PhenytoinThe metabolism of Promethazine can be increased when combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Promethazine.Approved
PimozidePromethazine may increase the QTc-prolonging activities of Pimozide.Approved
PindololPromethazine may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Promethazine.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Promethazine.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Promethazine.Approved
PizotifenThe risk or severity of adverse effects can be increased when Promethazine is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Promethazine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Promethazine.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Promethazine.Approved, Investigational, Vet Approved
PractololPromethazine may increase the hypotensive activities of Practolol.Approved
PramipexolePromethazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Promethazine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Promethazine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Promethazine.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Promethazine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Promethazine.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promethazine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Promethazine.Approved
PrimaquineThe serum concentration of Promethazine can be increased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Promethazine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePromethazine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Promethazine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promethazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Promethazine.Approved, Vet Approved
ProguanilThe serum concentration of Promethazine can be increased when it is combined with Proguanil.Approved
PromazinePromethazine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenonePromethazine may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Promethazine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Promethazine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Promethazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Promethazine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Promethazine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Promethazine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Promethazine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Promethazine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Promethazine.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Promethazine.Approved
PyrimethamineThe serum concentration of Promethazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Promethazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe serum concentration of Promethazine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapinePromethazine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Promethazine can be increased when it is combined with Quinacrine.Approved, Investigational
QuinidinePromethazine may increase the QTc-prolonging activities of Quinidine.Approved
QuininePromethazine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Promethazine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Promethazine.Investigational
RadicicolThe serum concentration of Promethazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Promethazine.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Promethazine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Promethazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Promethazine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promethazine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Promethazine.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Promethazine.Approved, Investigational
RifampicinThe metabolism of Promethazine can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Promethazine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Promethazine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Promethazine.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Promethazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Promethazine.Investigational
RitobegronRitobegron may decrease the sedative activities of Promethazine.Investigational
RitonavirThe metabolism of Promethazine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Promethazine.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promethazine.Approved
RolapitantThe metabolism of Promethazine can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Promethazine.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Promethazine.Vet Approved
RopinirolePromethazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promethazine.Approved
RotigotinePromethazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Promethazine.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Promethazine.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Promethazine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Promethazine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promethazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promethazine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Promethazine.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Promethazine.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Promethazine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Promethazine.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Promethazine.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Promethazine.Approved
SinefunginThe serum concentration of Promethazine can be increased when it is combined with Sinefungin.Experimental
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Promethazine.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Promethazine.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Promethazine.Approved, Investigational
SotalolPromethazine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Promethazine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Promethazine.Experimental
StiripentolThe metabolism of Promethazine can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.Approved, Investigational
SulfadoxineThe serum concentration of Promethazine can be increased when it is combined with Sulfadoxine.Approved, Investigational
SulfametopyrazineThe serum concentration of Promethazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazolePromethazine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Promethazine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Promethazine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Promethazine.Approved, Investigational
SuvorexantPromethazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Promethazine.Approved, Investigational
tafenoquineThe serum concentration of Promethazine can be increased when it is combined with tafenoquine.Investigational
TalinololPromethazine may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Promethazine.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Promethazine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Promethazine is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Promethazine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Promethazine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Promethazine.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Promethazine.Withdrawn
TelavancinPromethazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinPromethazine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Promethazine.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Promethazine.Approved
TerbinafineThe metabolism of Promethazine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololPromethazine may increase the hypotensive activities of Tertatolol.Experimental
TetrabenazinePromethazine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Promethazine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Promethazine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Promethazine.Investigational
ThalidomidePromethazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Promethazine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Promethazine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Promethazine.Approved, Withdrawn
ThiotepaThe metabolism of Promethazine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Promethazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Promethazine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Promethazine.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Promethazine.Approved
TiclopidineThe metabolism of Promethazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Promethazine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Promethazine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Promethazine.Approved
TipranavirThe metabolism of Promethazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Promethazine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Promethazine.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Promethazine.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Promethazine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Promethazine.Approved, Investigational
ToremifenePromethazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Promethazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Promethazine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promethazine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Promethazine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Promethazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Promethazine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Promethazine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Promethazine.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Promethazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Promethazine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Promethazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Promethazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promethazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Promethazine.Approved
TropisetronTropisetron may increase the serotonergic activities of Promethazine.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Promethazine.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Promethazine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Promethazine.Approved, Investigational
VandetanibPromethazine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Promethazine.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Promethazine.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Promethazine.Approved
VemurafenibPromethazine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Promethazine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Promethazine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Promethazine.Experimental
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Promethazine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Promethazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Promethazine is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Promethazine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Promethazine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Promethazine.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Promethazine.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Promethazine is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Promethazine.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Promethazine.Experimental
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Promethazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Promethazine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Promethazine is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Promethazine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Promethazine is combined with Zimelidine.Withdrawn
ZiprasidonePromethazine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Promethazine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promethazine.Approved, Investigational
ZolpidemPromethazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Promethazine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Promethazine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Promethazine.Approved
ZuclopenthixolPromethazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

References

Synthesis Reference
US2530451
General References
  1. Peters RJ Jr, Kelder SH, Markham CM, Yacoubian GS Jr, Peters LA, Ellis A: Beliefs and social norms about codeine and promethazine hydrochloride cough syrup (CPHCS) onset and perceived addiction among urban Houstonian adolescents: an addiction trend in the city of lean. J Drug Educ. 2003;33(4):415-25. [PubMed:15237866]
External Links
Human Metabolome Database
HMDB15202
KEGG Drug
D00494
KEGG Compound
C07404
PubChem Compound
4927
PubChem Substance
46507798
ChemSpider
4758
BindingDB
50017696
ChEBI
8461
ChEMBL
CHEMBL643
Therapeutic Targets Database
DAP000334
PharmGKB
PA451128
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Promethazine
ATC Codes
V03AB05 — Prednisolone and promethazineR06AD02 — PromethazineD04AA10 — PromethazineR06AD52 — Promethazine, combinations
AHFS Codes
  • 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
  • 04:04.12 — Phenothiazine Derivatives
FDA label
Download (93.4 KB)
MSDS
Download (74.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentAllergies1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentDiabetic Gastroparesis1
2, 3CompletedNot AvailableLabour Pain1
3CompletedPreventionNausea / Pain / Vomiting1
3CompletedTreatmentMigraine With Aura / Migraine Without Aura1
3CompletedTreatmentNausea / Pain / Vomiting1
3CompletedTreatmentVertigo, Peripheral1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentHyperemesis Gravidarum1
3Unknown StatusHealth Services ResearchSedation, Conscious1
4CompletedPreventionNausea / Postoperative Nausea and Vomiting (PONV)1
4CompletedPreventionProphylaxis against postoperative nausea and vomiting1
4CompletedTreatmentChronic Hepatitis C Infection With Hepatic Coma / Hepatic Failure / Hepatic Impairment1
4CompletedTreatmentNausea / Vomiting1
4CompletedTreatmentSnake Bites1
4SuspendedBasic ScienceVestibular1
Not AvailableCompletedTreatmentPsychomotor Agitation1
Not AvailableRecruitingPreventionProphylaxis against postoperative nausea and vomiting1
Not AvailableRecruitingSupportive CareCancer, Breast / Prophylaxis against postoperative nausea and vomiting1
Not AvailableTerminatedPreventionAmbulatory Gynecological Laparoscopic Procedures1
Not AvailableTerminatedPreventionNausea1
Not AvailableTerminatedTreatmentNausea1
Not AvailableUnknown StatusSupportive CareEndoscopic Retrograde Cholangiopancreatography (ERCP) / Endoscopic Ultrasound (EUS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral
SuppositoryRectal12.5 mg/1
SuppositoryRectal50 mg/1
CreamTopical2 %
SolutionIntramuscular; Intravenous25 mg
SyrupOral10 mg
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
SyrupOral
InjectionIntramuscular50 mg/mL
Injection, solutionIntravenous.5 mg/mL
Injection, solutionIntravenous.625 mg/mL
Injection, solutionIntravenous1 mg/mL
LiquidIntramuscular; Intravenous28.2 mg
InjectionIntramuscular25 mg/mL
InjectionIntramuscular; Intravenous25 mg/mL
InjectionIntramuscular; Intravenous50 mg/mL
Injection, solutionIntramuscular25 mg/1
Injection, solutionIntramuscular50 mg/mL
Injection, solutionIntramuscular; Intravenous25 mg/mL
Injection, solutionIntramuscular; Intravenous50 mg/mL
SolutionOral6.25 mg/5mL
SyrupOral6.25 mg/5mL
TabletOral12.5 mg/1
TabletOral25 mg/301
TabletOral25 mg/1
TabletOral50 1/1
TabletOral50 mg/1
SolutionOral
LiquidIntramuscular; Intravenous25 mg
LiquidOral
SuppositoryRectal25 mg/1
Prices
Unit descriptionCostUnit
Promethegan 12 50 mg Suppository Box101.64USD box
Phenergan 12 50 mg Suppository Box80.16USD box
Phenergan 12 25 mg Suppository Box62.59USD box
Promethegan 12 25 mg Suppository Box62.27USD box
Promethazine HCl 12 50 mg Suppository Box60.94USD box
Phenergan 12 12.5 mg Suppository Box54.58USD box
Phenergan 25 mg suppository8.32USD suppository
Promethegan 50 mg suppository8.14USD suppository
Phenergan 12.5 mg suppository7.94USD suppository
Phenergan 50 mg suppository7.39USD suppository
Promethazine 50 mg suppository4.88USD suppository
Promethegan 25 mg suppository4.62USD suppository
Phenadoz 25 mg suppository4.45USD suppository
Promethazine 25 mg suppository4.32USD suppository
Promethegan 12.5 mg suppository4.02USD suppository
Promethazine HCl 12.5 mg Suppository4.0USD suppository
Phenadoz 12.5 mg suppository3.89USD suppository
Phenergan 25 mg/ml ampul3.84USD ml
Promethazine 12.5 mg suppository3.82USD suppository
Phenergan 50 mg/ml ampul3.68USD ml
Promethazine HCl 50 mg/ml Solution 1ml Ampule2.8USD ampule
Promethazine 50 mg/ml ampul2.25USD ml
Promethazine hcl powder2.14USD g
Promethazine 25 mg/ml ampul1.1USD ml
Promethazine 25 mg/ml1.06USD ml
Promethazine HCl 50 mg tablet0.81USD tablet
Promethazine 50 mg tablet0.78USD tablet
Promethazine HCl 25 mg tablet0.73USD tablet
Phenergan 25 mg tablet0.62USD tablet
Promethazine 25 mg tablet0.51USD tablet
Promethazine 12.5 mg tablet0.49USD tablet
Promethazine-DM 6.25-15 mg/5ml Syrup0.18USD ml
Promethazine HCl 6.25 mg/5ml Syrup0.11USD ml
Promethazine VC Plain 6.25-5 mg/5ml Syrup0.09USD ml
Promethazine-Codeine 6.25-10 mg/5ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)60 °CPhysProp
boiling point (°C)190-192 °C at 3.00E+00 mm HgPhysProp
water solubility15.6 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.81HANSCH,C ET AL. (1995)
logS-4.26ADME Research, USCD
pKa9.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0245 mg/mLALOGPS
logP4.52ALOGPS
logP4.29ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity88.5 m3·mol-1ChemAxon
Polarizability32.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9832
Blood Brain Barrier+0.9855
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.8157
P-glycoprotein inhibitor IInhibitor0.8408
P-glycoprotein inhibitor IINon-inhibitor0.6473
Renal organic cation transporterInhibitor0.5156
CYP450 2C9 substrateNon-substrate0.7736
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.5338
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9341
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.567
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.9088
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6959 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9786
hERG inhibition (predictor II)Inhibitor0.7661
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.88 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - CI-BGC-MSsplash10-000i-0090000000-f1fe9756bed13819bbb4
GC-MS Spectrum - EI-BGC-MSsplash10-00di-9000000000-abbdf5514dccef4821b2
GC-MS Spectrum - EI-BGC-MSsplash10-00di-9100000000-9bef9a6b83d662fc7e2c
GC-MS Spectrum - CI-BGC-MSsplash10-0079-8290000000-fe5d6b4e9f62b7270798
Mass Spectrum (Electron Ionization)MSsplash10-00di-9210000000-7167670dff3395a6ade2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000j-0690000000-0b4dfbac9712d2e36046
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-9220000000-9d761be1437f10dcc94b

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / Benzenoids / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / Para-thiazine / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Thioether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, tertiary amine (CHEBI:8461)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K: Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. [PubMed:12657913]
  3. Smith BN, Armstrong WE: Histamine enhances the depolarizing afterpotential of immunohistochemically identified vasopressin neurons in the rat supraoptic nucleus via H1-receptor activation. Neuroscience. 1993 Apr;53(3):855-64. [PubMed:8098142]
  4. Miller RA, Tu AT: Factors in snake venoms that increase capillary permeability. J Pharm Pharmacol. 1989 Nov;41(11):792-4. [PubMed:2576052]
  5. Claro E, Arbones L, Garcia A, Picatoste F: Phosphoinositide hydrolysis mediated by histamine H1-receptors in rat brain cortex. Eur J Pharmacol. 1986 Apr 16;123(2):187-96. [PubMed:3011460]
  6. Ikeda H, Kubo N, Nakamura A, Harada N, Minamino M, Yamashita T: Histamine-induced calcium released from cultured human mucosal microvascular endothelial cells from nasal inferior turbinate. Acta Otolaryngol. 1997 Nov;117(6):864-70. [PubMed:9442829]
  7. Paton DM, Webster DR: Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985 Nov-Dec;10(6):477-97. [PubMed:2866055]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Golembiewski JA, O'Brien D: A systematic approach to the management of postoperative nausea and vomiting. J Perianesth Nurs. 2002 Dec;17(6):364-76. [PubMed:12476402]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Unknown
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Bileviciute I, Stenfors C, Theodorsson E, Lundeberg T: Unilateral injection of calcitonin gene-related peptide (CGRP) induces bilateral oedema formation and release of CGRP-like immunoreactivity in the rat hindpaw. Br J Pharmacol. 1998 Nov;125(6):1304-12. [PubMed:9863661]
  2. Kelley BM, Porter JH: The role of muscarinic cholinergic receptors in the discriminative stimulus properties of clozapine in rats. Pharmacol Biochem Behav. 1997 Aug;57(4):707-19. [PubMed:9258998]
  3. Hoenicke EM, Vanecek SA, Woods JH: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. J Pharmacol Exp Ther. 1992 Oct;263(1):276-84. [PubMed:1403790]
  4. Martinez F, Coleman JW: A comparison of the effects of chlorpromazine and more selective histamine and 5-hydroxytryptamine antagonists on human IgG synthesis in vitro. Int J Immunopharmacol. 1990;12(2):185-91. [PubMed:2329012]
  5. Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl). 1995 Oct;121(3):347-56. [PubMed:8584617]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Cohen ME, Sharp GW, Donowitz M: Suggestion of a role for calmodulin and phosphorylation in regulation of rabbit ileal electrolyte transport: effects of promethazine. Am J Physiol. 1986 Nov;251(5 Pt 1):G710-7. [PubMed:3022601]
  2. Scott JA, Khaw BA, Fallon JT, Locke E, Rabito CA, Peto CA, Homcy CJ: The effect of phenothiazines upon maintenance of membrane integrity in the cultured myocardial cell. J Mol Cell Cardiol. 1986 Dec;18(12):1243-54. [PubMed:3820316]
  3. Lohr KM, Feix JB, Kurth C: Chlorpromazine inhibits neutrophil chemotaxis beyond the chemotactic receptor-ligand interaction. J Infect Dis. 1984 Nov;150(5):643-52. [PubMed:6092486]
  4. DiPaola M, Keith CH, Feldman D, Tycko B, Maxfield FR: Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. J Cell Physiol. 1984 Feb;118(2):193-202. [PubMed:6319437]
  5. Luchowski EM, Yousif F, Triggle DJ, Maurer SC, Sarmiento JG, Janis RA: Effects of metal cations and calmodulin antagonists on [3H] nitrendipine binding in smooth and cardiac muscle. J Pharmacol Exp Ther. 1984 Sep;230(3):607-13. [PubMed:6433001]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Dick W, Lorenz W, Heintz D, Sitter H, Doenicke A: [Histamine release during induction of combination anesthesia using nalbuphine or fentanyl. Modulation of the reaction by premedication with promethazine/pethidine]. Anaesthesist. 1992;41(5):239-47. [PubMed:1377455]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Platts SH, Shi SJ, Meck JV: Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. [PubMed:16670408]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49